Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Kangyang Lin"'
Autor:
Jingping Hu, Jinyuan Wu, Han Cao, Ning Luan, Kangyang Lin, Haihao Zhang, Dandan Gao, Zhentao Lei, Hongjun Li, Cunbao Liu
Publikováno v:
Vaccines, Vol 12, Iss 9, p 1025 (2024)
Diarrheal disease continues to be a major cause of global morbidity and mortality among children under 5 years of age. To address the current issues associated with oral attenuated rotavirus vaccines, the study of parenteral rotavirus vaccines has pr
Externí odkaz:
https://doaj.org/article/dbc6d662bd734fb399c7f83d439565bd
Publikováno v:
Vaccines, Vol 11, Iss 9, p 1475 (2023)
Cell-mediated immunity (CMI) plays a key role in the effectiveness of varicella zoster virus (VZV) vaccines, and mRNA vaccines have an innate advantage in inducing CMI. Glycoprotein E (gE) has been used widely as an antigen for VZV vaccines, and carb
Externí odkaz:
https://doaj.org/article/b7c344c26cb045ebb8462debed8c209c
Publikováno v:
Viruses, Vol 15, Iss 6, p 1351 (2023)
A large amount of real-world data suggests that the emergence of variants of concern (VOCs) has brought new challenges to the fight against SARS-CoV-2 because the immune protection elicited by the existing coronavirus disease 2019 (COVID-19) vaccines
Externí odkaz:
https://doaj.org/article/237856da67a5455e802d01f47289d310
Publikováno v:
Vaccines, Vol 11, Iss 5, p 1003 (2023)
Previous studies have shown that the herpes zoster subunit vaccine Shingrix™ performs well in clinical trials. However, the key ingredient in its adjuvant, QS21, is extracted from rare plants in South America, so vaccine production is limited. Comp
Externí odkaz:
https://doaj.org/article/4d8cf89581cc49c4b4f1147eb5d8659f
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The relatively lower protection rate of the alum-adjuvanted inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines reminds us of the antibody-dependent enhancement (ADE) phenomenon observed in preclinical studies during the
Externí odkaz:
https://doaj.org/article/e208b3702ecc45ec9ffa3314c6e5c5f3
Publikováno v:
Pharmaceutics, Vol 14, Iss 5, p 973 (2022)
Varicella zoster virus (VZV) causes two diseases: varicella upon primary infection and herpes zoster when latent viruses in the sensory ganglia reactivate. While varicella vaccines depend on humoral immunity to prevent VZV infection, cell-mediated im
Externí odkaz:
https://doaj.org/article/ff30020d3bd34beb9faad179ce3b95a9
Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy
Publikováno v:
Vaccines, Vol 9, Iss 12, p 1440 (2021)
Glycoprotein E (gE) is one of the most abundant glycoproteins in varicella-zoster virus and plays pivotal roles in virus replication and transmission between ganglia cells. Its extracellular domain has been successfully used as an antigen in subunit
Externí odkaz:
https://doaj.org/article/7d5a79a18c3541c7a309db5b3b5f9118
Publikováno v:
Vaccines, Vol 9, Iss 11, p 1261 (2021)
A recently reported parallel preclinical study between a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine and an inactivated SARS-CoV-2 vaccine adjuvanted with alum showed pulmonary immunopathology typical of eosinophil accum
Externí odkaz:
https://doaj.org/article/5ceb0ef61a884eefadfdc00ad3a3b079
Publikováno v:
Viruses; Volume 15; Issue 6; Pages: 1351
A large amount of real-world data suggests that the emergence of variants of concern (VOCs) has brought new challenges to the fight against SARS-CoV-2 because the immune protection elicited by the existing coronavirus disease 2019 (COVID-19) vaccines
Publikováno v:
Journal of Medical Virology. 94:2250-2258
Waning antibodies and rapidly emerging variants are challenges for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine development. Adjusting existing immunization schedules and further boosting strategies are under consideration. He